Skip to main content Help with accessibility Skip to main navigation

Upadacitinib

Indication

Treating active ankylosing spondylitis - NICE TA829

NICE TA829 - Upadacitinib for treating active ankylosing spondylitis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Red

Brand:

Nice TA:

829

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Musculoskeletal system

Background

1.1 Upadacitinib is recommended as an option for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults, only if:

tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and

the company provides upadacitinib according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD
BP
CSR
EL
FW
GP
MB
WL
Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 14 - Nov - 2022